Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


 

ASCO GU 2018: Renal Cell Carcinoma News Program

22/03/2018

This year the ASCO Genitourinary Cancers Symposium took place in San Francisco from February 8th - 10th. In this Renal Cell Carcinoma News Program, we focus on the highlights for RCC at this congress. Moderator Catherine Hood and a panel of international experts discuss the following topics: Adjuvant systemic therapy Cabozantinib in the first line treatment of metastatic RCC The NIVOREN trial that investigates nivolumab in a ‘real world setting’ Combination treatments with VEGF and PD1/PD-L1 inhibition Advances in treatment for papillary RCC Speakers: Prof. Joaquim Bellmunt, MD, medical oncologist, Dana-Farber/Brigham and Women's Cancer Center, Boston Daniel George, MD, medical oncologist, Duke Cancer Center, Durham Jeanny Aragon-Ching, MD, medical oncologist, Inova Fairfax hospital, Fairfax Sumanta Pal, MD, medical oncologist, City of Hope Comprehensive Cancer Center, Duarte Moderator: Catherine Hood

  • 00:39:40
 

WCM 2017 Highlights: Biomarker immunotherapy

22/03/2018

The 9th World Congress of Melanoma (WCM) was held in Brisbane, Australia, from 18 to 21 October. In a series of interviews medical professionals from all over the world discussed the latest developments in the field of melanoma. This highlight consists of the following parts: Michele Teng, PhD – research scientist, QIMR Berghofer Medical Research Institute, Brisbane, Australia: Why does immunotherapy works so well for melanoma? Prof. Levesque Mitchell, MD – dermatologist, University of Zurich Hospital, Zürich, Switzerland: High dimensional single-cell analysis identifies classical monocyte frequencies to be predictive of PFS to anti-PD-1 immunotherapy Prof. Nikolas Haass, MD – dermatologist, University of Queensland, Brisbane, Australia: Tumor heterogeneity, plasticity and drug resistance

  • 00:16:35
 

ESMO 2017 in-depth: KEYNOTE-040 trial

12/09/2017

This year the ESMO congress took place in Madrid from 8 - 12 September. E. This phase III trial evaluated the efficacy of checkpoint inhibitor pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma after platinum-based chemotherapy.

  • 00:08:50
 

Clinical updates from the EHA 2017 part 1

25/06/2017

The 22nd European Hematology Association (EHA) took place in Madrid, Spain, on 22-25 June 2017. An international multidisciplinary panel discussed a selection of topics and new data on hematology during a live program. They gave an answer to what this newly acquired knowledge means for clinical practice. Topics New immunotherapy data for lymphoma The mechanisms behind iron overload New diagnostic markers for ITP Speakers Alicia Rovó, MD – hematologist, University Hospital of Bern, Bern, Switzerland Sigrid Machherndl-Spandl, MD – hematologist, Elisabethinen Hospital, Linz, Austria Moderator Prof. Harry Schouten, MD – hematologist, Maastricht UMC+, Maastricht, The Netherlands

  • 00:50:48

Click here to select your areas of interest

Areas of interest

Select to filter on program types

Quarterly focus 19/12/2018

Quarterly Focus on Genitourinary Cancer: highlights in prostate carcinoma (part 2)

In each Quarterly Focus MEDtalks Oncology brings you the unique opportunity to gain more insight into two pivotal publications on Genitourinary Cancer. In the fourth episode (watch episode 1 on prostate cancer (part 1), episode 2 on renal cell carcinoma and episode 3 on bladder cancer on-demand) two international publications on prostate cancer from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. During the live broadcast on Wednesday 19th of December 8.30-9.30 PM CEST you have the possibility to interact with our expert panel and the authors and ask them your questions. The expert panel consist of: Niven Mehra, MD, PhD – medical oncologist, Radboudumc, Nijmegen Andre Bergman, MD, PhD – medical oncologist, Netherlands Cancer Institute, Amsterdam Theo de Reijke, MD, PhD - urologist, AMC, Amsterdam program: Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer (LATITUDE) N Engl J M, July 27, 2017 Speaker: Karim Fizazi, MD, PhD - medical oncologist, Gustave Roussy Institute, Villejuif, France Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial The Lancet, Oct 21, 2018 Speaker: Prof. Nicholas James, PhD - medical oncologist, University of Birmingham, UK Sign up for this live program

Quarterly focus 21/11/2018

Quarterly Focus on GU | Bladder Cancer

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Oncology has developed a new program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data. In this third episode of the Quarterly Focus on Genitourinary Cancer, two pivotal, international publications on Bladder Cancer from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. The expert panel consist of: Michiel van der Heijden, MD, PhD - medical oncologist, Netherlands Cancer Institute, Amsterdam Prof. Fred Witjes, MD -  urologist, Radboudumc, Nijmegen Sjoukje Oosting, MD, PhD - medical oncologist, UMCG, Groningen Program: Speaker: Prof. Dipen Parekh, MD – urologist at University of Miami Health System in Miami, USA Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial Lancet 391, 2018 Speaker: Michiel van der Heijden, MD, PhD, medical oncologist, Netherlands Cancer Institute, Amsterdam, The Netherlands Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial Lancet 391, 2017

Congresnieuws 06/11/2018

ESMO 2018 in depth: Checkmate 142

Heinz-Josef Lenz, MD, oncologist at USC, Norris Comprehensive Cancer Center in Los Angeles provides information on the Checkmate 142. A study of nivolumab plus ipilimumab as first-line therapy in MSI-H/dMMR metastatic colorectal cancer. 

Congresnieuws 06/11/2018

ESMO 2018 in depth: IMpower 130

Federico Cappuzzo, MD, oncologist at AUSL Romagna in Ravenna, provides information on the IMpower130. A study of carboplatin + nab-paclitaxel with or without atezolizumab as first-line therapy in advanced NSCLC.   

Quarterly focus 12/09/2018

E-learning: Quarterly Focus on Genitourinary Cancer | RCC

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Oncology has developed a new program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data. In this second episode of the Quarterly Focus on Genitourinary Cancer, two pivotal, international publications on Renal Cell Carcinoma from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. The expert panel consist of: Prof. John Haanen, MD, PhD, medical oncologist, Netherlands Cancer Institute, Amsterdam Hans Westgeest, MD, medical oncologist, Amphia Ziekenhuis, Breda Astrid van der Veldt, MD, PhD, medical oncologist, Erasmus MC, Rotterdam Program: Invited speaker: Kathleen Mahoney, MD, PhD, medical oncologist, Beth Israel Deaconess Medical Center, Boston Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma N Engl J Med 378, 2018 Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma Nature Medicine 24, 2018

Congresnieuws 27/06/2018

ASCO 2018 Rechallenge with bevacizumab in ovarian cancer

Dr. Sandro Pignata, oncologist and president of the Multicentre Italian Trial in Ovarian cancer (MITO) group, explains the results of the MITO 16b trial. This study evaluated whether the addition of bevacizumab to a platinum-based chemotherapy prolongs survival for recurrent ovarian cancer patients who had already received it during first line.

Congresnieuws 27/06/2018

ASCO 2018 Results of the TAILORx trial

Joseph Sparano, oncologist at Montefiore Medical Center, explains the results of the TAILORx trial, which he presented during the plenary session at ASCO 2018. This trial attempted to incorporate a gene expression test into clinic decision making for hormone receptor positive breast cancer.

Quarterly focus 07/06/2018

E-learning: Quarterly Focus on Hemato-Oncology | Highlights in AML 2018

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Hematology has developed a program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data. Three high-impact, recent international publications on two main topics in AML will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. During this live broadcast you will have the unique opportunity to interact with our expert panel and the authors and ask them your questions. The studio expert panel consists of: Prof. Gert Ossenkoppele, MD, PhD, hematologist, VUmc Amsterdam, The Netherlands Bas Wouters, MD, PhD, hematologist, ErasmusMC Rotterdam, The Netherlands Peter Valk, PhD, molecular biologist in hematology, ErasmusMC Rotterdam, The Netherlands Live video guests: Courtney Dinardo, MD, hemato-oncologist, MD Anderson Cancer Center, Houston, US Eytan Stein, MD, hemato-oncologist, MSKCC, New York, US Prof. Christian Thiede MD, PhD, professor in molecular hematology, Universitätsklinikum Dresden, Germany

Quarterly focus 23/05/2018

E-learning: Quarterly Focus on Genitourinary Cancer | Prostate Cancer

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Oncology has developed a new program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data. Two pivotal, international publications from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. The expert panel consist of: André Bergman MD, PhD, medical oncologist, Netherlands Cancer Institute, Amsterdam Martijn Lolkema MD, PhD, medical oncologist, Erasmus MC, Rotterdam Niven Mehra MD, PhD, medical oncologist, Radboudumc, Nijmegen Program: Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial J Clin Oncol 36, 2018 Speaker: Prof. Gert De Meerleer MD, PhD, radiation oncologist, UZ Leuven, Belgium Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide J Clin Oncol 35, 2017 Speaker: Jun Luo MD, PhD, cell and molecular biologist, Brady Urological Institute, US

Quarterly focus 22/03/2018

E-learning: Quarterly Focus on Breast Cancer

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not have always sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks.eu/OncologyTV has developed a new program format, the 'Quarterly Focus', which brings together an expert panel and the authors of relevant, selected publications in an innovative way to explain and discuss the new data. Two pivotal, international publications from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the unique possibility to gain more insight into the selected publications and to interact with the expert panel and the authors. The expert panel consists of: Gabe Sonke, MD, Ph.D, medical oncologist, NKI-AVL Amsterdam, Netherlands Ester Siemerink, MD, Ph.D, medical oncologist, Ziekenhuis Groep Twente, Hengelo/Almelo, Netherlands Rianne Oosterkamp, MD, medical oncologist, Haaglanden Medisch Centrum, Den Haag, Netherlands Invited speakers: Prof. George Sledge, MD, medical oncologist Stanford University School of Medicine, California, US MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy J Clin Oncol, 2017 Prof. Laura van 't Veer, molecular biologist UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades JAMA Oncol, 2017

Quarterly focus 22/03/2018

Quarterly Focus on Hemato-Oncology | Highlights in AML

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not have always sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks.eu has developed a new program format, the 'Quarterly Focus, which brings together an expert panel and the authors of relevant, selected publications in an innovative way to explain and discuss the new data. The selection for the first edition of Quarterly Focus on Hemato-Oncology has been made by prof. dr. Gert Ossenkoppele, VUmc Amsterdam, Netherlands. Three pivotal, international publications from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the unique possibility to gain more insight into the selected publications and to interact with the expert panel and the authors. The expert panel consists of: Prof. Gert Ossenkoppele, MD, hematologist, VUmc, Amsterdam, Netherlands; Prof. Gerwin Huls, MD, hematologist, UMCG, Groningen; Netherlands; Peter Valk, Ph.D., molecular biologist, Erasmus MC, Rotterdam, Netherlands. Selected publications Quarterly Hemato-Oncology: Midostaurin plus chemotherapy for acute myeloid leukemia with FLT mutation N Engl J Med 2017 Prof. Richard Schlenk, MD, hematologist TP53 and decitabine in AML and myelodysplastic syndromes N Engl J Med 2016 Dr. John S. Welch, MD, Ph.D., hematologist Precision Oncology in acute myeloid leukemia using a knowledge bank approach. Nature Genetics, January 2017 Elli Papaemmanuil, Ph.D., molecular geneticist Accreditation: This program will be submitted for accreditation at the EBAH and Dutch NIV.